Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Cervical Cancer
What dose fractionation would you use on a large retroperitoneal recurrence of cervical cancer that is extending to previously treated 5040cGy pelvis?
Answer from: Radiation Oncologist at Community Practice
Favor starting with chemotherapy, and planning RT based on response to chemo as volume and dose can be adjusted based on response.
Comments
Radiation Oncologist at New York Cancer and Blood Specialists
After chemotherapy, the dose and fractionations wi...
Radiation Oncologist at Tacoma/Valley Radiation Oncology Centers
Thank you Dr. @Sushil Beriwal. Chemotherapy did sh...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Yes, that is one option. I favor concurrent chemo ...
Radiation Oncologist at Alabama Cancer Care
I discussed this case with our main GYN attending,...
5314
5316
5318
5332
Sign in or Register to read more
10714
Related Questions
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
Would you offer post operative radiation for a patient who had findings of lymphovascular invasion on salvage resection of a recurrent obturator node after definitive chemoradiation for cervical cancer?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
How would you utilize brachytherapy boost in addition to EBRT for HPV-dependent invasive squamous cell carcinoma present as a large pelvic side wall mass, presumed to be of cervix primary, albeit the negative biopsies of the cervix?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
What are some considerations for planning T&O brachytherapy in a patient with bilateral hip replacements, where it is difficult to delineate disease on MRI and even surrounding structures on CT?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
After chemotherapy, the dose and fractionations wi...
Thank you Dr. @Sushil Beriwal. Chemotherapy did sh...
Yes, that is one option. I favor concurrent chemo ...
I discussed this case with our main GYN attending,...